Immunotoxins based on the IgG response to autologous antigens in cancer patients

基于癌症患者对自体抗原的 IgG 反应的免疫毒素

基本信息

批准号：
9251785
负责人：
SCOTT Kendall DESSAIN
金额：
$ 22.53万
依托单位：
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9251785
关键词：
Address Affinity Alpha Cell Amino Acids Antibodies Antibody Response Antibody-drug conjugates Antigen Targeting Antigens Aspergillus Autoantigens B lymphocyte immortalization B-Lymphocytes Bacterial Toxins Binding Biodistribution Cancer Etiology Cancer Patient Cancer cell line Cell Line Cell hybridization Cell surface Cells Cessation of life Characteristics Clinical Cloning Colon Carcinoma Computer Simulation Dose Drug Kinetics GPA33 gene Generations Human Hybrid Cells Immune system Immunoglobulin G Immunoprecipitation Immunotoxins In Vitro Malignant Neoplasms Malignant neoplasm of lung Measures Methods Modeling Molds Monoclonal Antibodies Mus Mutate Mycotoxins Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Normal Cell Patients Performance Personal Communication Phenotype Process Protein Isoforms Proteins RNA Splicing Recombinants Research Safety Solid Neoplasm Specificity Structure T-Lymphocyte T-Lymphocyte Epitopes Testing Therapeutic Toxic effect Toxin Trastuzumab Tumor Antigens United States Xenograft Model Xenograft procedure base bevacizumab cDNA Library cancer cell cancer immunotherapy cancer stem cell cancer therapy cell killing chimeric antigen receptor clinical development cytotoxic efficacy testing experimental study glycosylation human monoclonal antibodies immunogenicity in vitro activity in vitro testing in vivo killings lymph nodes malignant breast neoplasm mouse model novel overexpression public health relevance response screening success tumor tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States, but the promise of therapies based on monoclonal antibodies (mAbs) has been unrealized due to the lack of known antibody targets specific for lung cancer cells. This research will address this need by characterizing three new lung cancer-specific mAbs that were cloned from patients with cancer and have shown cytotoxic activity in vitro when converted into antibody drug conjugates. We will convert them into immunotoxins and test them for and determine their specificity, safety and efficacy against lung cancer.

描述（由适用提供）：肺癌是美国癌症死亡的主要原因，但是由于缺乏针对肺癌细胞特异的已知抗体靶标，基于单克隆抗体（MAB）的疗法的承诺已经未实现。这项研究将通过表征从癌症患者克隆的三个新的肺癌特异性mAB来解决这一需求，并在转化为抗体药物共轭物时在体外显示出细胞毒性活性。我们将将它们转化为免疫毒素，并测试它们并确定它们针对肺癌的特异性，安全性和效率。